ATHA
Income statement / Annual
Last year (2023), Athira Pharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Athira Pharma, Inc.'s net income was -$117.67 M.
See Athira Pharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$969,000.00 |
$1.05 M |
$479,000.00 |
$2.00 M |
$0.00 |
$0.00 |
| Gross Profit |
-$969,000.00 |
-$1.05 M |
-$479,000.00 |
-$2.00 M |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$92.82 M
|
$61.46 M
|
$42.79 M
|
$13.29 M
|
$3.79 M
|
$3.59 M
|
| General & Administrative
Expenses |
$33.30 M
|
$32.55 M
|
$21.23 M
|
$6.71 M
|
$1.66 M
|
$1.42 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$33.30 M
|
$32.55 M
|
$21.23 M
|
$6.71 M
|
$1.66 M
|
$1.42 M
|
| Other Expenses |
-$1.63 M |
-$5.16 M |
-$8.84 M |
-$1.32 M |
-$754,000.00 |
-$164,000.00 |
| Operating Expenses |
$125.47 M |
$88.86 M |
$55.19 M |
$18.67 M |
$4.70 M |
$5.01 M |
| Cost And Expenses |
$125.47 M |
$88.86 M |
$55.19 M |
$18.67 M |
$4.70 M |
$5.01 M |
| Interest Income |
$7.64 M |
$3.22 M |
$337,000.00 |
$124,000.00 |
$51,000.00 |
$85,000.00 |
| Interest Expense |
$0.00 |
$24.32 M |
$3,000.00 |
$367,000.00 |
$346,000.00 |
$9,000.00 |
| Depreciation &
Amortization |
$969,000.00
|
$1.05 M
|
$479,000.00
|
$2.00 M
|
$2,000.00
|
$5.01 M
|
| EBITDA |
-$116.70 M
|
-$94.59 M
|
-$54.37 M
|
-$19.01 M
|
-$4.82 M
|
-$79,000.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$7.79 M
|
$8.38 M
|
$9.17 M
|
$40,000.00
|
$288,000.00
|
-$88,000.00
|
| Income Before Tax |
-$117.67 M |
-$95.64 M |
-$54.85 M |
-$19.96 M |
-$5.16 M |
-$5.10 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$8.38 M |
-$479,000.00 |
-$1.32 M |
-$459,000.00 |
-$76,000.00 |
| Net Income |
-$117.67 M |
-$87.26 M |
-$54.37 M |
-$18.63 M |
-$4.70 M |
-$5.10 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-3.1 |
-2.31 |
-1.47 |
-0.57 |
-0.14 |
-0.82 |
| EPS Diluted |
-3.09 |
-2.31 |
-1.47 |
-0.57 |
-0.14 |
-0.82 |
| Weighted Average Shares
Out |
$38.02 M
|
$37.73 M
|
$36.92 M
|
$32.49 M
|
$32.62 M
|
$6.19 M
|
| Weighted Average Shares
Out Diluted |
$38.02 M
|
$37.73 M
|
$36.92 M
|
$32.49 M
|
$32.62 M
|
$6.19 M
|
| Link |
|
|
|
|
|
|
